The week in pharma: action, reaction and insight – week to January 20, 2023

22 January 2023

By Barbara Obstoj-Cardwell. Editor

M&A news featured in the past week, with the announcement that Leap Therapeutics is to merge with Flame Biosciences, with the aim of advancing its anti-claudin 18.2 asset. Also, Elicio Therapeutics entered into a reverse merger deal with Angion Biomedica, which will see the former list on the Nasdaq. Additionally, India’s Sun Pharmaceutical Industries is shelling out $576 million to acquire Concert Pharmaceuticals and its alopecia candidate deuruxolitinib. Meanwhile, US mRNA vaccine specialist Moderna released positive new data on its respiratory syncytial virus (RSV) vaccine. On the regulatory front, the US Food and Drug Administration (FDA) declined to grant accelerated approval for Eli Lilly’s Alzheimer’s candidate donanemab, issuing a complete response letter CRL.

Claudin 18.2 continues to fan the dealmaking flames

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK